This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- LAZCLUZE (lazertinib) is a kinase inhibitor indicated in combination with RYBREVANT (amivantamab-vmjw) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (Exon19del) or Exon 21 L858R substitution mutations, as detected by a United States Food and Drug Administration (FDA)-approved test.1
- LAZCLUZE is not commercially available as a solution or suspension.
- Swallow LAZCLUZE tablets whole. Do not crush, split, or chew tablets.1
- LAZCLUZE 80 mg or 240 mg tablet(s) can be dispersed in non-carbonated water for patients who have difficulty swallowing.1
- The company cannot support any practices, procedures, or dosage administration techniques that deviate from the approved product labeling.
- Please refer to the DOSAGE AND ADMINISTRATION section of the full Prescribing Information for complete information.1
Alternate Method of PREPARATION AND ADMINISTRATION
LAZCLUZE Tablets Prepared as a Dispersion in Water1
- Place the tablet(s) required for the prescribed dose of LAZCLUZE into a small drinking cup.
- Add at least 2 teaspoons (10 mL) of non-carbonated water.
- Swirl gently until the tablet(s) are dispersed into small pieces. It may take up to 2 minutes to disperse the tablet(s).
- Administer immediately after preparation.
- Add at least 1 teaspoon (5 mL) of non-carbonated water to the same cup, swirl gently to suspend any remaining particles, then administer immediately to ensure that the full dose is received.
- Discard any unused dispersion if not administered within 1 hour of preparation.
PRODUCT LABELING
Literature Search
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 13 November 2026.